Ozempic, Wegovy, Mounjaro—the names are everywhere, from doctor’s offices to dinner-table conversations. These GLP-1 drugs have transformed diabetes and weight-loss treatment, helping millions control blood sugar and shed pounds. But new studies suggest they may carry an unexpected risk: sudden and sometimes irreversible vision loss.
What damage can occur?
The condition in question is non-arteritic anterior ischemic optic neuropathy (NAION), often described as an “eye stroke.” It occurs when blood flow to the optic nerve is suddenly reduced or blocked.
Unlike gradual eye diseases, NAION strikes quickly—often noticed upon waking, when patients suddenly lose vision in one eye. The outlook is grim: vision typically stabilizes after a few weeks, but 70% of people never regain what they lost.
People with diabetes already face a higher risk, and currently, there are no approved treatments for NAION.
What earlier research revealed
In 2024, a study found patients prescribed semaglutide for diabetes were four times more likely to develop NAION. Those taking it for weight loss faced an almost eightfold risk.
By June, the European Medicines Agency had officially recognized NAION as a very rare side effect (around 1 in 10,000). Drug labels were updated to reflect the warning.
Researchers also flagged another concern: these medications may worsen diabetic retinopathy, a complication of uncontrolled blood sugar that damages retinal vessels and can lead to blindness.
Ironically, rapid drops in blood sugar may destabilize already fragile retinal vessels, increasing the chance of bleeding.
What the new studies show
Two major studies analyzed health records of 159,000 to 185,000 Americans with type 2 diabetes.
One found only a small increased risk of NAION among GLP-1 users: 35 patients out of 159,000 (0.04%) developed NAION, compared to 19 patients (0.02%) in the control group. It also found higher rates of “other optic nerve disorders,” though the data didn’t specify exactly which.
The second study, however, reported no link at all between GLP-1 use and NAION.
What both studies did observe was a slight uptick in diabetic retinopathy cases among GLP-1 patients. But importantly, these patients had fewer severe eye complications and needed less invasive treatment than those on other diabetes medications.
Long-term risks remain uncertain. A five-year trial with 1,500 participants is underway to determine whether these drugs truly influence diabetic eye disease in the long run.
What this means if you’re taking GLP-1 drugs
Balancing risks and benefits is key. GLP-1 medications save lives by treating diabetes, reducing obesity, and lowering heart attack risk. But patients with multiple NAION risk factors—such as sleep apnea, hypertension, and diabetes—should have careful discussions with their doctors before starting therapy.
Another red flag? People with “crowded” optic nerve heads, where vessels are tightly packed, are more vulnerable. Regular eye exams are critical, both to monitor for diabetic retinopathy and to identify at-risk optic nerves.
Doctors recommend that patients disclose GLP-1 use to their eye specialists and seek immediate care for sudden vision loss. Managing heart health—through cholesterol control, blood pressure treatment, and sleep apnea care—may also help reduce risks.
Why it matters
GLP-1 medications remain powerful tools in diabetes and obesity management. But the possibility of an “eye stroke,” even if rare, underscores the need for vigilance. As research continues, patients and doctors must weigh the undeniable benefits of these drugs against the small but serious risks they pose to eye health.
link